|
Delayed
Nasdaq
00:00:00 15/08/2025 +04
|
5-day change | 1st Jan Change | ||
| 100.99 USD | +0.01% |
|
-.--% | - |
| Market Cap | 3.32B 2.97B 2.76B 2.51B 4.74B 321B 4.76B 33.21B 13.01B 164B 12.47B 12.2B 526B | P/E 2023 |
-317x | P/E 2024 | 69.3x |
|---|---|---|---|---|---|
| Enterprise Value | 3.48B 3.11B 2.89B 2.63B 4.96B 337B 4.98B 34.77B 13.62B 172B 13.06B 12.77B 551B | EV / Sales 2023 |
1.55x | EV / Sales 2024 | 1.33x |
| Free-Float |
-
| Yield 2023 * |
-
| Yield 2024 | - |
| 30/09/25 | A CEO's Playbook For Navigating Crisis And Building Trust (Video) | AQ |
| 30/07/25 | Amedisys: Q2 Earnings Snapshot | AQ |
| 30/07/25 | Amedisys : Second Quarter 2025 Earnings Release Supplemental Slides | PU |
| 30/07/25 | Amedisys Reports Second Quarter 2025 Financial Results | AQ |
| 24/04/25 | Amedisys: Q1 Earnings Snapshot | AQ |
| 1 day | +0.01% |
| 3 years | 82.15 |  | 101.02 |
| 5 years | 69.36 | | 188.88 |
| 10 years | 34.58 | | 325.12 |
| Manager | Title | Age | Since |
|---|---|---|---|
Scott Ginn
DFI | Director of Finance/CFO | 57 | 06/10/2017 |
Keith Blanchard
CTO | Chief Tech/Sci/R&D Officer | - | - |
Denise Bohnert
CMP | Compliance Officer | 48 | 01/01/2017 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 14/08/25 | Issuer sale | Director | 9,818 | 0.0300% | ||
| 14/08/25 | Issuer sale | Director | 9,818 | 0.0300% | ||
| 14/08/25 | Issuer sale | Chief Executive Officer | 520,347 | 1.5886% |
| 2023 | 2024 | |
|---|---|---|
| Net sales | 2.24B 2B 1.86B 1.69B 3.19B 216B 3.2B 22.36B 8.76B 110B 8.4B 8.21B 354B | 2.35B 2.1B 1.95B 1.77B 3.35B 227B 3.37B 23.48B 9.2B 116B 8.82B 8.63B 372B |
| Net income | -9.75M -8.71M -8.1M -7.37M -13.91M -943M -13.97M -97.46M -38.19M -481M -36.6M -35.8M -1.54B | 43.23M 38.61M 35.92M 32.67M 61.68M 4.18B 61.95M 432M 169M 2.13B 162M 159M 6.85B |
| Net Debt | 361M 322M 300M 273M 515M 34.91B 517M 3.61B 1.41B 17.8B 1.35B 1.33B 57.12B | 156M 139M 130M 118M 223M 15.1B 224M 1.56B 611M 7.7B 586M 573M 24.71B |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
- Stock Market
- Stocks
- AMED Stock
Select your edition
All financial news and data tailored to specific country editions
